Firms
Theme

COO

The Cooper Companies, Inc. · NASDAQ

$61.21USDCS band Mixed

↓ $0.44 (0.71%)

Last close · Oct 23, 4:00 PM ET

Sign up free to see this.

Mkt Cap
$11.6B
Volume
1.4M
52W High
$89.83
52W Low
$51.01
PE Ratio
20.4
Avg Vol
4.1M
As of 10/23/26
Div Yield
—
Beta
0.44
As of 10/23/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about COO?

Latest news

News ›

GlobeNewswire Inc.

The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm has launched an investigation into potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) following allegations of materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, resulting in a 14.6% stock decline. The firm is preparing a class action lawsuit to recover investor losses on a contingency fee basis.

GlobeNewswire Inc.

The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' disappointing earnings report on September 10, 2026, which included weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

Zacks Investment Research

Why Is The Cooper Companies (COO) Up 0.2% Since Last Earnings Report?

The Cooper Companies reported Q3 fiscal 2026 adjusted EPS of $1.15, beating estimates by 3.6%, but revenues of $1.066 billion missed consensus by 3.0%. The CooperVision segment faced pressure from U.S. channel inventory reductions, while CooperSurgical showed steady growth. Downward estimate revisions and a Zacks Rank #5 (Strong Sell) rating reflect investor concerns about near-term performance.

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $COO · 0 threads

Sign in to post on $COO

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev